Small Molecule Therapeutics for Renal Disease

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$264,578.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK079399-01
Award Id:
85583
Agency Tracking Number:
DK079399
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ANGION BIOMEDICA CORP, 1050 Stewart Ave., Garden City, NY, 11530
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
053129065
Principal Investigator:
PRAKASH NARAYAN
(516) 326-1200
PNARAYAN@ANGION.COM
Business Contact:
ITXHAK GOLDBERG
() -
igoldberg@angion.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Progressive renal disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if a ny, of the currently practiced therapeutic strategies oppose the molecular and cellular programs of apoptosis and fibrosis that drive renal disease. Scatter factor/hepatocyte growth factor (SF/HGF), is a renotrophic factor with anti-apoptotic and anti-fibr otic properties. However clinical feasibility of SF/HGF administration as gene or protein therapy is limited by issues relating to the immune and inflammatory responses evoked by adenoviral proteins, inherent instability of proteins in solution, their limi ted tissue half-life and exorbitant costs. Using a drug-discovery engine comprising 3-dimensional molecular modeling, phage display, rational drug design, targeted proteomics and in vitro biology, Angion Biomedica Corp. has identified two, chemically disti nct, small molecules that activate the SF/HGF receptor c-Met. These drug candidates activate the SF/HGF/c-Met signaling cascade, and exert cytoprotective and anti-fibrotic effects in vitro. Preliminary data in an in vivo model of progressive renal disease indicate that these small molecule SF/HGF mimetics oppose interstitial collagen deposition and preserve renal function. Preliminary data from regulatory safety studies suggest that these chemical class members are safe and well-tolerated. Using rational dr ug-design based chemical substitutions, we have now constructed structural libraries around these small molecules. The goal of this Phase I application is to couple in vitro targeted proteomics to in vivo bioefficacy studies in order to identify a lead SF/ HGF mimetic within each chemical class, with the eventual goal of bringing an SF/HGF mimetic to clinical trials for the treatment of progressive renal disease. A small molecule anti-fibrotic has significant clinical potential for the treatment of progressi ve renal disease.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government